GO:0048010 vascular endothelial growth factor receptor signaling pathway: Angiogenesis Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048010 describes the molecular signal transduction cascade initiated when a VEGF ligand binds a VEGFR on the cell surface, culminating in regulation of downstream cellular processes such as transcription.
• VEGFR2 (KDR/FLK1) is the principal receptor mediating VEGF-A-driven endothelial proliferation, migration, survival, and vascular permeability.
• VEGFR1 (FLT1) and VEGFR3 (FLT4) modulate the pathway: VEGFR1 can act as a decoy/negative regulator, while VEGFR3 governs lymphatic and specialized endothelial functions partly through beta-arrestin 1.
• The pathway is central to physiological angiogenesis and is dysregulated in cancer, retinopathies, and nephrotoxicity associated with anti-VEGF therapies.
• Core signaling arms include PLCgamma-ERK, PI3K-AKT, and SRC/FAK cascades that together drive endothelial gene expression and cytoskeletal remodeling.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of VEGFR pathway components in endothelial and disease-relevant cells.
Description
The vascular endothelial growth factor receptor (VEGFR) signaling pathway, annotated as GO:0048010, is the biological process that begins with VEGF ligand binding to a VEGFR at the cell surface and ends with regulation of a downstream cellular process such as transcription. This pathway is the principal molecular engine of angiogenesis, the formation of new blood vessels from pre-existing vasculature, and it also controls vascular permeability, endothelial survival, and lymphatic development. Because angiogenesis is required for tumor growth, wound healing, and normal development, VEGFR signaling is one of the most intensively studied receptor tyrosine kinase pathways in biomedicine. At the molecular level, VEGF-A binding to VEGFR2 triggers receptor dimerization, autophosphorylation, and recruitment of adaptor proteins that activate PLCgamma-ERK, PI3K-AKT, and SRC/FAK signaling arms. These cascades converge on transcription factors such as NFAT, ETS, and HIF-responsive programs that reshape endothelial gene expression, promote proliferation and migration, and increase vessel permeability. VEGFR1 and VEGFR3 add layers of regulation: VEGFR1 can sequester VEGF-A and dampen VEGFR2 signaling, while VEGFR3 controls lymphatic endothelial and specialized vascular functions through beta-arrestin 1. For researchers, GO:0048010 provides a structured framework to interpret how genetic or pharmacological perturbations alter endothelial behavior. Anti-VEGF agents such as bevacizumab illustrate the pathway's clinical importance and its on-target toxicities, including nephrotoxicity and hypertension. Understanding which VEGFR pathway components are causally required for a given phenotype therefore demands precise, editable cell models and functional readouts.
vascular endothelial growth factor receptor signaling pathway At A Glance
| GO ID | GO:0048010 |
|---|---|
| GO term | vascular endothelial growth factor receptor signaling pathway |
| Ontology | biological_process |
| Synonym | VEGF receptor signaling pathway; VEGF receptor signalling pathway; VEGFR signaling pathway |
| Definition | The series of molecular signals initiated by a ligand binding to a vascular endothelial growth factor receptor (VEGFR) on the surface of the target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| Major function | Transduces VEGF ligand binding into endothelial proliferation, migration, survival, permeability, and transcriptional programs that drive angiogenesis and lymphangiogenesis. |
| Key receptors | VEGFR1 (FLT1), VEGFR2 (KDR/FLK1), VEGFR3 (FLT4). |
| Key ligands | VEGF-A, VEGF-B, VEGF-C, VEGF-D, PlGF, and viral VEGF-E. |
| Primary cell context | Vascular endothelial cells, lymphatic endothelial cells, and selected non-endothelial cell types. |
| Disease relevance | Cancer angiogenesis, retinopathies, nephrotoxicity from anti-VEGF therapy, and developmental vascular disorders. |
What Is GO:0048010?
GO:0048010, vascular endothelial growth factor receptor signaling pathway, is defined as the series of molecular signals initiated by a ligand binding to a vascular endothelial growth factor receptor (VEGFR) on the surface of the target cell, and ending with the regulation of a downstream cellular process, for example transcription. In practical terms, it covers the receptor-proximal events (ligand binding, receptor dimerization, autophosphorylation), the intracellular relay (adaptor recruitment, kinase cascade activation), and the downstream transcriptional and cytoskeletal outputs that together constitute a complete VEGFR signal.
Why Is vascular endothelial growth factor receptor signaling pathway Important in Cell Biology?
GO:0048010 is important because it defines the molecular route by which VEGF family ligands control blood and lymphatic vessel formation, permeability, and endothelial survival, processes that are essential in development and are co-opted in cancer, ocular neovascular disease, and other angiogenesis-dependent pathologies. The pathway is also the direct target of approved therapeutics such as bevacizumab and VEGFR kinase inhibitors, making a precise understanding of its components essential for predicting efficacy and on-target toxicities like nephrotoxicity.
• Drives physiological angiogenesis during embryonic development, wound healing, and the female reproductive cycle.
• Supports tumor angiogenesis, providing oxygen and nutrients to growing solid tumors.
• Controls vascular permeability and edema through SRC/FAK and junctional remodeling.
• Regulates lymphatic endothelial development and function via VEGFR3 and beta-arrestin 1.
• Is the mechanistic basis for anti-VEGF and anti-VEGFR therapeutics in oncology and ophthalmology.
• Mediates on-target toxicities such as hypertension, proteinuria, and nephrotoxicity during VEGF inhibition.
• Provides a model receptor tyrosine kinase pathway for studying signal transduction, feedback, and crosstalk.
• Interacts with PDGF and other growth factor systems in pericyte recruitment and vessel maturation.
• Serves as a benchmark for CRISPR functional genomics of endothelial signaling.
• Informs biomarker and resistance studies in glioblastoma and other VEGF-driven tumors.
What Happens During vascular endothelial growth factor receptor signaling pathway?
Ligand binding and receptor dimerization
In simple terms: VEGF grabs the receptor on the outside of the cell and pulls two receptors together.
The pathway begins when a VEGF family ligand, most commonly VEGF-A, binds the extracellular immunoglobulin-like domains of a VEGFR on the target cell surface. Ligand binding induces receptor dimerization, which is a prerequisite for activation of the intracellular kinase domains. VEGFR2 is the principal signaling receptor for VEGF-A in endothelial cells, whereas VEGFR1 binds VEGF-A with high affinity but can act as a negative regulator or decoy, and VEGFR3 is activated primarily by VEGF-C and VEGF-D in lymphatic and specialized endothelia.
Receptor autophosphorylation and adaptor recruitment
In simple terms: The paired receptors switch on by adding phosphate tags to each other, creating docking sites for helper proteins.
Dimerization enables trans-autophosphorylation of specific tyrosine residues in the VEGFR2 intracellular domain, generating phosphotyrosine docking sites for SH2-domain-containing adaptors such as PLCgamma, GRB2, and SRC. These adaptor interactions nucleate distinct signaling complexes that determine which downstream arms are engaged. VEGFR1 can also be phosphorylated but its kinase activity and downstream output are comparatively weak, consistent with a modulatory role.
Activation of PLCgamma-ERK and PI3K-AKT arms
In simple terms: The receptor sends two main internal signals: one that tells the cell to grow and divide, and one that tells it to survive.
Phospholipase C gamma (PLCgamma) hydrolyzes PIP2 to IP3 and DAG, mobilizing calcium and activating PKC, which in turn feeds into the RAF-MEK-ERK cascade to drive proliferation. In parallel, PI3K generates PIP3, recruiting AKT and its regulators to promote endothelial survival, migration, and nitric oxide production. These arms are not isolated; they exhibit crosstalk and feedback that shape the duration and amplitude of the response.
Cytoskeletal remodeling and permeability control
In simple terms: The signal loosens the connections between cells and reorganizes their skeleton so they can move and let fluid through.
VEGFR2 activation recruits SRC and FAK, which phosphorylate junctional and focal adhesion proteins, leading to transient disruption of VE-cadherin-based endothelial junctions and increased vascular permeability. Actin cytoskeletal reorganization, mediated by Rho-family GTPases and downstream effectors, enables endothelial cell migration and sprouting. These events are essential for both physiological angiogenesis and pathological edema.
Transcriptional outputs and feedback regulation
In simple terms: The signal reaches the nucleus and changes which genes are turned on or off, including genes that can dial the signal back down.
ERK and other kinases translocate to the nucleus and activate transcription factors such as ETS-family proteins, NFAT, and AP-1, reprogramming endothelial gene expression to support proliferation, migration, and survival. Negative feedback loops, including induction of DUSP phosphatases and SOCS proteins, and receptor internalization/degradation, terminate or tune the signal. VEGFR3 signaling through beta-arrestin 1 provides an additional layer of regulation in specialized endothelia.
Key Genes Involved in GO:0048010 vascular endothelial growth factor receptor signaling pathway
The following genes encode the ligands, receptors, adaptors, and downstream effectors that constitute or directly regulate GO:0048010.
| Gene | Major Role | Research Relevance |
|---|---|---|
| VEGFA | Primary ligand for VEGFR2; drives angiogenesis and permeability | Most studied VEGF family ligand; target of anti-angiogenic strategies |
| KDR (VEGFR2) | Principal signaling receptor for VEGF-A in endothelial cells | Central node of GO:0048010; key CRISPR knockout target |
| FLT1 (VEGFR1) | High-affinity VEGF-A receptor that can act as decoy/negative regulator | Modulates pathway output; relevant to preeclampsia and cancer |
| FLT4 (VEGFR3) | Receptor for VEGF-C/VEGF-D; regulates lymphatic and specialized endothelium | Signals partly through beta-arrestin 1 |
| PLCG1 | Hydrolyzes PIP2 to IP3 and DAG downstream of VEGFR2 | Links receptor to calcium/PKC and ERK arms |
| PIK3CA | Catalytic subunit of PI3K generating PIP3 | Drives AKT-dependent survival and migration |
| AKT1 | Serine/threonine kinase mediating survival and metabolic outputs | Readout of PI3K arm; frequently studied by phospho-AKT |
| SRC | Non-receptor tyrosine kinase regulating permeability and junctions | Key effector of VEGFR2-driven vascular leak |
| PTK2 (FAK) | Focal adhesion kinase controlling migration and adhesion turnover | Cytoskeletal readout of VEGFR2 signaling |
| GRB2 | Adaptor coupling VEGFR2 to RAS-MAPK cascade | Essential for ERK activation |
| PDPK1 | Kinase required for full AKT activation | Component of PI3K-AKT arm |
| NRP1 | Co-receptor enhancing VEGF-A binding to VEGFR2 | Modulates pathway sensitivity |
| NRP2 | Co-receptor for VEGF-C/VEGF-D and VEGFR3 | Lymphatic signaling modulator |
| PDGFB | Pericyte-recruiting ligand cooperating with VEGF in vessel maturation | Crosstalk with PDGF pathway |
| HIF1A | Transcription factor inducing VEGFA under hypoxia | Upstream regulator of ligand availability |
| DUSP1 | Phosphatase that dephosphorylates ERK | Negative feedback node |
| ARRB1 | Beta-arrestin 1 mediating VEGFR3 signaling | Regulates endothelial function downstream of VEGFR3 |
How Is vascular endothelial growth factor receptor signaling pathway Regulated?
GO:0048010 is regulated at multiple levels. Ligand availability is controlled transcriptionally by hypoxia-inducible factors such as HIF1A, which induce VEGFA under low oxygen. Receptor abundance and activity are tuned by internalization, ubiquitination, and degradation, as well as by co-receptors such as NRP1 and NRP2 that modulate ligand-receptor affinity. Negative feedback phosphatases including DUSP1 dampen ERK signaling, while beta-arrestin 1 provides a scaffold that shapes VEGFR3 output. Crosstalk with the PDGF pathway influences pericyte recruitment and vessel stabilization, adding another layer of regulation to VEGF-driven angiogenesis.
vascular endothelial growth factor receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| VEGFA | Tumor angiogenesis; glioblastoma; retinopathy | VEGFA knockout or overexpression in endothelial and tumor cell lines |
| KDR (VEGFR2) | Angiogenesis-dependent cancers; vascular permeability | KDR knockout and point-mutation endothelial cells |
| FLT1 (VEGFR1) | Preeclampsia; cancer modulation | FLT1 knockout and decoy-domain knock-in models |
| FLT4 (VEGFR3) | Lymphedema; lymphatic dysfunction | FLT4 knockout and ARRB1 interaction mutants |
| SRC | Vascular leak; edema in inflammation and tumors | SRC knockout endothelial cells with permeability assays |
Cancer and tumor angiogenesis
Solid tumors frequently overexpress VEGF-A and rely on VEGFR2 signaling to recruit new blood vessels, making GO:0048010 a central driver of tumor growth and a major therapeutic target. Bevacizumab, a VEGF-A-neutralizing antibody, has been evaluated in malignant brain gliomas and other cancers, illustrating both the pathway's importance and the challenges of resistance and toxicity. VEGFR kinase inhibitors similarly block this pathway but can cause hypertension and nephrotoxicity.
Renal and cardiovascular toxicity of VEGF inhibition
Therapeutic inhibition of VEGF signaling is associated with nephrotoxicities including proteinuria, hypertension, and thrombotic microangiopathy, reflecting the pathway's requirement for glomerular endothelial health. These on-target effects highlight the need to understand which VEGFR pathway components mediate protective versus pathological outputs.
Lymphatic and developmental vascular disorders
VEGFR3 signaling through beta-arrestin 1 regulates endothelial function and lymphatic development, and its disruption contributes to lymphedema and related vascular anomalies. Because VEGFR1 and VEGFR2 also shape developmental angiogenesis, pathway perturbations can produce embryonic vascular defects.
From vascular endothelial growth factor receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is KDR required for VEGF-A-induced ERK activation? | KDR knockout endothelial cell line |
| Does a specific VEGFR2 phosphotyrosine mediate PI3K-AKT signaling? | Point-mutation knock-in of the tyrosine to phenylalanine |
| How does a disease-associated FLT4 variant alter beta-arrestin 1 coupling? | Knock-in of the variant allele in endothelial cells |
| Where does VEGFR2 localize after ligand stimulation? | Tagged knock-in of KDR with a fluorescent or epitope tag |
| Does VEGFA overexpression increase angiogenic sprouting? | VEGFA overexpression in endothelial or tumor cells |
| Which genes buffer VEGFR pathway output? | CRISPR library screening in VEGF-stimulated endothelial cells |
How to Study the vascular endothelial growth factor receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Immunoblotting | Phosphorylation of VEGFR2, ERK, AKT | Pathway activation after VEGF stimulation |
| Phosphoproteomics | Global tyrosine phosphorylation changes | Mapping VEGFR2 signaling networks |
| RNA-seq | Transcriptional outputs of VEGFR signaling | Identifying pathway target genes |
| Tube formation assay | Endothelial morphogenesis in vitro | Angiogenesis phenotyping |
| Transendothelial permeability assay | Barrier function and leak | Permeability regulation by SRC/FAK |
| Live-cell imaging | Receptor trafficking and localization | VEGFR2 internalization studies |
| CRISPR library screening | Genes required for VEGF responses | Discovery of pathway modifiers |
| In vivo zebrafish angiogenesis | Developmental vessel formation | Genetic dissection of VEGFR pathway |
Phospho-proteomics and receptor activation assays
Immunoblotting and mass spectrometry-based phosphoproteomics measure VEGFR2 autophosphorylation and downstream phospho-ERK and phospho-AKT levels after VEGF stimulation, providing direct readouts of pathway engagement.
Transcriptomic profiling of endothelial responses
RNA-seq after VEGF stimulation identifies transcriptional outputs of GO:0048010, including immediate-early genes and feedback regulators, and can be combined with CRISPR perturbations to link specific pathway components to gene expression programs.
Functional angiogenesis and permeability assays
Tube formation, spheroid sprouting, transwell migration, and transendothelial electrical resistance or dextran flux assays quantify the cellular behaviors driven by VEGFR signaling.
Imaging of receptor trafficking and vascular phenotypes
Live-cell imaging of tagged VEGFR2 tracks internalization and trafficking, while in vivo imaging of zebrafish or mouse vasculature assesses developmental and pathological angiogenesis.
How CRISPR Can Be Used to Study GO:0048010 vascular endothelial growth factor receptor signaling pathway
Knockout
CRISPR knockout of KDR, FLT1, FLT4, or downstream effectors such as PLCG1 and SRC provides loss-of-function models to test which components are required for VEGF-induced proliferation, migration, and permeability. Knockout endothelial cells are widely used to validate pathway dependencies before in vivo studies.
Point Mutation
Point-mutation knock-in of specific VEGFR2 tyrosine residues to phenylalanine allows dissection of which phosphotyrosine docking sites mediate PI3K-AKT versus PLCgamma-ERK outputs, a classic approach in receptor tyrosine kinase biology.
Knock-in
Knock-in of disease-associated FLT4 or KDR variants, or of epitope/fluorescent tags, enables allele-specific functional studies and real-time tracking of receptor localization and turnover in endothelial cells.
Overexpression
Overexpression of VEGFA or constitutively active VEGFR2 constructs models ligand-driven or ligand-independent pathway activation, useful for studying angiogenic sprouting, tumor microenvironment remodeling, and resistance mechanisms.
How EDITGENE Supports vascular endothelial growth factor receptor signaling pathway Research
Researchers studying vascular endothelial growth factor receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in VEGF responses or is merely correlated with them. EDITGENE provides publication-ready CRISPR cell models and screening services that let you move from hypothesis to causal evidence in endothelial and disease-relevant cell backgrounds.
Contact EDITGENE today to design your custom CRISPR model for vascular endothelial growth factor receptor signaling pathway research.
Frequently Asked Questions About vascular endothelial growth factor receptor signaling pathway
What is GO:0048010?
GO:0048010 is the Gene Ontology biological process term for vascular endothelial growth factor receptor signaling pathway, defined as the series of molecular signals initiated by ligand binding to a VEGFR on the target cell surface and ending with regulation of a downstream cellular process such as transcription.
What genes are involved in vascular endothelial growth factor receptor signaling pathway?
Key genes include VEGFA, KDR (VEGFR2), FLT1 (VEGFR1), FLT4 (VEGFR3), PLCG1, PIK3CA, AKT1, SRC, PTK2 (FAK), GRB2, NRP1, NRP2, and ARRB1.
Which receptor is the main mediator of VEGF signaling?
VEGFR2 (KDR/FLK1) is the principal receptor mediating VEGF-A-driven endothelial proliferation, migration, survival, and permeability.
How does VEGFR2 signal inside the cell?
Ligand binding induces VEGFR2 dimerization and autophosphorylation, recruiting adaptors that activate PLCgamma-ERK, PI3K-AKT, and SRC/FAK cascades.
What is the role of VEGFR1 in this pathway?
VEGFR1 (FLT1) binds VEGF-A with high affinity but can act as a decoy or negative regulator that modulates VEGFR2 output.
How is VEGFR3 involved in endothelial function?
VEGFR3 (FLT4) responds to VEGF-C and VEGF-D and regulates lymphatic and specialized endothelial functions partly through beta-arrestin 1.
Why is VEGFR signaling important in cancer?
Tumors rely on VEGFR-driven angiogenesis for growth, making this pathway a major target of anti-angiogenic therapies such as bevacizumab and VEGFR kinase inhibitors.
What are the side effects of inhibiting VEGF signaling?
Therapeutic VEGF inhibition is associated with nephrotoxicity, hypertension, and proteinuria due to on-target effects on glomerular endothelium.
How do researchers study VEGFR signaling in the lab?
Common methods include phospho-immunoblotting, phosphoproteomics, RNA-seq, tube formation and permeability assays, live-cell imaging, and CRISPR screens.
Can CRISPR be used to study VEGFR pathway genes?
Yes. CRISPR knockout, point-mutation knock-in, tagged knock-in, and overexpression models are widely used to dissect VEGFR pathway component functions.
Conclusion
GO:0048010, vascular endothelial growth factor receptor signaling pathway, is a foundational biological process that converts VEGF ligand binding into endothelial proliferation, migration, survival, permeability, and transcriptional reprogramming. Its central role in angiogenesis makes it a key research area in cancer, vascular biology, and drug toxicity, and its receptor-proximal architecture makes it an ideal system for mechanistic dissection. By combining CRISPR knockout, point-mutation, knock-in, overexpression, and library screening approaches with functional and omics readouts, researchers can move from correlation to causation for any VEGFR pathway component. EDITGENE supports this workflow with publication-ready cell models and bioinformatics tailored to vascular endothelial growth factor receptor signaling pathway research.
References
- 1. Estrada CC et al.. 2019. Therapeutic Inhibition of VEGF Signaling and Associated Nephrotoxicities.. J Am Soc Nephrol 30(2):187-200 PMID: 30642877
- 2. Roskoski R Jr. 2025. Vascular endothelial cells and angiogenesis.. Pharmacol Res 221:107983 PMID: 41077163
- 3. Ferrara N et al.. 2003. The biology of VEGF and its receptors.. Nat Med 9(6):669-76 PMID: 12778165
- 4. Andrae J et al.. 2008. Role of platelet-derived growth factors in physiology and medicine.. Genes Dev 22(10):1276-312 PMID: 18483217
- 5. Karaman S et al.. 2018. Vascular endothelial growth factor signaling in development and disease.. Development 145(14) PMID: 30030240
- 6. Shibuya M. 2006. Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E.. Endothelium 13(2):63-9 PMID: 16728325
- 7. Koukourakis GV. 2015. Bevacizumab for Malignant Brain Gliomas. Which is the Current Evidence?. Recent Pat Inflamm Allergy Drug Discov 9(2):136-43 PMID: 26256461
- 8. Ma Z et al.. 2019. Vascular Endothelial Growth Factor Receptor 3 Regulates Endothelial Function Through β-Arrestin 1.. Circulation 139(13):1629-1642 PMID: 30586762
